Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Pincus, T ^a   Furer, V ^a   Sokka, T ^b,c  

^a NEW YORK UNIVERSITY   (United States)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^c Finland MedCare Ltd   (Finland)

Author keywords

Effectiveness; Efficacy; Low dose; Methotrexate; Weekly low dose

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; AURANOFIN; AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ABATACEPT; ADALIMUMAB; ANAKINRA; CERTOLIZUMAB PEGOL; GOLIMUMAB; RITUXIMAB; SALICYLIC ACID; TOCILIZUMAB;

ACCURACY; ADRENAL SUPPRESSION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; BLOOD CELL COUNT; BLOOD DISEASE; BONE MARROW SUPPRESSION; BONE RADIOGRAPHY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFORMATION; DRUG MONITORING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE PERSONNEL; HUMAN; INFECTION; KIDNEY DISEASE; LIVER DISEASE; LIVER FUNCTION TEST; LIVER INJURY; LONG TERM CARE; LOW DRUG DOSE; LUNG DISEASE; META ANALYSIS (TOPIC); MOUTH ULCER; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN DISEASE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ADRENAL DISEASE; ADVERSE OUTCOME; CLINICAL EFFECTIVENESS; DISEASE COURSE; DISEASE DURATION; DRUG PROTEIN BINDING; DRUG SURVEILLANCE PROGRAM; ERYTHROCYTE SEDIMENTATION RATE; INFECTION RISK; PSORIATIC ARTHRITIS; RISK BENEFIT ANALYSIS; TREATMENT DURATION;

ALCOHOL DRINKING; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; CONSUMER PRODUCT SAFETY; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; EVIDENCE-BASED MEDICINE; FOLIC ACID; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; META-ANALYSIS AS TOPIC; METHOTREXATE; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; RHEUMATIC DISEASES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 78650574250     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (114)

1. PINCUS T, YAZICI Y, SOKKA T, ALETAHA D, SMOLEN JS: Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21: S179-S185.
2. VISSER K, KATCHAMART W, LOZA E et al.: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
3. OLSEN NJ, STEIN CM: New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
4. SOKKA T, KAUTIAINEN H, TOLOZA S et al.: QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in IS countries. Ann Rheum Dis 2007;66:1491-6. (Pubitemid 350032658)
5. PINCUS T, MARCUM SB, CALLAHAN LF: Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol 1992;19:1885-94. (Pubitemid 23018519)
6. DUCLOS M, GOSSEC L, RUYSSEN-WITRAND A et al.: Retention rates of TNF blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006;33:2433-9.
7. YAZICI Y, SOKKA T, KAUTIAINEN H, SWEARINGEN C, KULMAN I, PINCUS T: Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005;64:207-11.
8. PINCUS T, CALLAHAN LF, SALE WG, BROOKS AL, PAYNE LE, VAUGHN WK: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
9. RASKER JJ, COSH JA: The natural history of rheumatoid arthritis: a fifteen year followup study. The prognostic significance of features noted in the first year. Clin Rheumatol 1984;3:11-20.
10. SCOTT DL, GRINDULIS KA, STRUTHERS GR, COULTON BL, POPERT AJ, BACON PA: Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 1984;43:8-17.
11. SOKKA T, KAUTIAINEN H, HANNONEN P: Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved long-term outcomes of rheumatoid arthritis. Ann Rheum Dis 2007;66:341-4.
12. YELIN E, MEENAN R, NEVITT M, EPSTEIN W: Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980;93:551-6.
13. SCOTT DL, COULTON BL, CHAPMAN JH, BACON PA, POPERT AJ: The long-term effects of treating rheumatoid arthritis. JR Coll Physicians Lond 1983;17:79-85.
14. BERGSTROM U, BOOK C, LINDROTH Y, MARSAL L, SAXNE T, JACOBSSON L: Lower disease activity and disability in Swedish patients with rheumatoid arthritis in 1995 compared with 1978. Scand J Rheumatol 1999;28:160-5.
15. SOKKA TM, KAARELA K, MOTTONEN TT, HANNONEN PJ: Conventional monotherapy compared to a "sawtooth" treatment strategy in the radiographic procession of rheumatoid arthritis over the first eight years. Clin Exp Rheumatol 1999;17:527-32.
16. KRISHNAN E, FRIES JF: Reduction in longterm functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med 2003;115:371-6.
17. SOKKA T, KAUTIAINEN H, HÄKKINEN K, HANNONEN P: Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J Rheumatol 2004;31:1073-82.
18. PINCUS T, SOKKA T, KAUTIAINEN H: Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005;52:1009-19.
19. KRAUSE D, SCHLEUSSER B, HERBORN G, RAU R: Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000;43:14-21.
20. CHOI HK, HERNÁN MA, SEEGER JD, ROBINS JM, WOLFE F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
21. WILSKE KR, HEALEY LA: Remodeling the pyramid - a concept whose time has come. J Rheumatol 1989;16:565-7.
22. PINCUS T, CALLAHAN LF: Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis - lessons from Hodgkin's disease and coronary artery disease. J Rheumatol 1990;17:1582-5.
23. FRIES JF: Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. J Rheumatol 1990;17(Suppl. 22):12-5.
24. PINCUS T: The case for early intervention in rheumatoid arthritis. J Autoimmun 1992;5(Suppl. A): 209-26.
25. PINCUS T: Rheumatoid arthritis: A medical emergency? Scand J Rheumatol 1994;23(Suppl. 100):21-30.
26. EMERY P, SALMON M: Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995;54:944-7.
27. WEINBLATTME: Rheumatoid arthritis: Treat now, not later! (editorial). Ann Intern Med 1996;124:773-4.
28. EMERY P, PANAYI G, STURROCK R, WILLIAMS B: Targeted therapies in rheumatoid arthritis: The need for action. Rheumatology 1999;38:911-2.
29. PINCUS T, SOKKA T, KAVANAUGH A: Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for "near remission" of DAS or single measures. Clin Exp Rheumatol 2004;22(Suppl. 35): S50-S56.
30. SMOLEN JS, ALETAHA D, BULSMA JW et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
31. SILMAN A, DAVIES P, CURREY H L F, EVANS S J W: Is rheumatoid arthritis becoming less severe? J Chronic Dis 1983;36:891-7.
32. SILMAN AJ: Trends in the incidence and severity of rheumatoid arthritis. J Rheumatol 1992;19(Suppl. 32):71-3.
33. UHLIG T, KVIEN TK: Has rheumatoid arthritis become a milder disease? Drug Discovery Today 2005;2:331-6.
34. FELSON DT, ANDERSON JJ, MEENAN RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990;33:1449-61.
35. SOKKA T, PINCUS T: Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. Rheumatology (Oxford) 2008;47:1543-7.
36. WILLIAMS HJ, WARD JR, READING JC et al.: Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992;35:259-69.
37. DONAHUE KE, GARTLEHNER G, JONAS DE et al.: Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-34.
38. GUYATT G, GUTTERMAN D, BAUMANN MH et al.: Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest 2006;129:174-81. (Pubitemid 43265259)
39. PINCUS T, YAZICI Y, SOKKA T: Are excellent systematic reviews of clinical trials useful for patient care? Nat Clin Pract Rheumatol 2008;4:294-5.
40. PINCUS T, SOKKA T: Clinical trials in rheumatic diseases: designs and limitations. Rheum Dis Clin N Am 2004;30:701-4.
41. FREIMAN JA, CHALMERS TC, SMITH H, JR, KUEBLER RR: The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: survey of 71 "negative" trials. N Engl J Med 1978;299:690-4.
42. FREIREICH EJ: The randomized clinical trial as an obstacle to clinical research. In: VARCO RL, DELANEY JP (Eds.): Controversy in Surgery. Philadelphia, Saunders. W. B., 1983, pp. 5-12.
43. FEINSTEIN AR: An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med 1983;99:544-50.
44. ROTHWELL PM: Can overall results of clinical trials be applied to all patients? Lancet 1995;345:1616-9.
45. FEINSTEIN AR, HORWITZ RI: Problems in the "evidence" of "evidence-based medicine". Am J Med 1997;103:529-35.
46. KAPTCHUK TJ: The double-blind, randomized, placebo-controlled trial: gold standard or golden calf? J Clin Epidemiol 2001;54:541-9.
47. SIDEROWF AD: Evidence from clinical trials: can we do better? NeuroRx 2004;1:363-71.
48. KEMM J: The limitations of 'evidence-based' public health. J Eval Clin Pract 2006;12:319-24.
49. MACK MJ: Clinical trials versus registries in coronary revascularization: which are more relevant? Curr Opin Cardiol 2007;22:524-8.
50. SANSON-FISHER RW, BONEVSKI B, GREEN LW, D'ESTE C: Limitations of the randomized controlled trial in evaluating population-based health interventions. Am J Prev Med 2007;33:155-61.
51. VANDENBROUCKE J: When are observational studies as credible as randomised trials? Lancet 2004;363:1728-31.
52. PINCUS T: Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988;41:1037-41.
53. PINCUS T, WOLFE F: Response to letter: Gold therapy for rheumatoid arthritis: Challenges to traditional paradigms. Ann Intern Med 1992;117:169-70.
54. PINCUS T: Limitations of randomized controlled clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum 1993;23(Suppl. 1):2-10.
55. PINCUS T, STEIN M: What is the best source of useful data on the treatment of rheumatoid arthritis: Clinical trials, clinical observations, or clinical protocols? J Rheumatol 1995;22:1611-7.
56. PINCUS T: Analyzing long-term outcomes of clinical care without randomized controlled clinical trials: The consecutive patient questionnaire database. Advances 1997;13:3-32.
57. PINCUS T, STEIN CM: Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: Some explanations and suggestions for future studies. Clin Exp Rheumatol 1997;15(Suppl. 17): S27-S38.
58. BURKE A, SMYTH E, FITZGERALD GA: Analgesic-antipyretic agents; pharmacotherapy of gout. In BRUNTON LL. LAZO JS, PARKER KL, (Eds.): Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, McGraw-Hill, 2006: pp. 671-716.
59. PINCUS T, MARCUM SB, CALLAHAN LF et al.: Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal anti-inflammatory drugs. J Rheumatol 1992;19:1874-84. (Pubitemid 23018518)
60. PINCUS T, CALLAHAN LF: The 'side effects' of rheumatoid arthritis: Joint destruction, disability and early mortality. Br J Rheumatol 1993;32: (Suppl. 1):28-37.
61. TILLING L, TOWNSEND S, DAVID J: Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006;26:55-62.
62. RAJAKULENDRAN S, GADSBY K, DEIGHTON C: Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified? Musculoskeletal Care 2008;6:233-45.
63. WILFRED DE ALVVIS NM, DAY CP: Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007;27:044-54.
64. SAAG KG, TENG GG, PATKAR NM et al.: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
65. STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
66. O'DELL JR, HAIRE CE, ERIKSON N et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
67. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
68. TUGWELL P, PINCUS T, YOCUM D et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
69. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. Lancet 1999;354:1932-9.
70. COHEN S, HURD E, CUSH J et al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
71. BOERS M, VERHOEVEN AC, MARKUSSE HM et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
72. MÖTTÖNEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
73. TUGWELL P, BOMBARDIER C, GENT M et al.: Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990;335:1051-5.
74. AHERNM J. HARRISON W. HOLLINGSWORTH P, BRADLEY J, LAING B, BAYLISS C: A randomized double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis. Aust N Z J Med 1991;21:844-9.
75. ZEIDLER HK, KVIEN TK, HANNONEN P et al.: Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: Comparison of lowdose cyclosporin and parenteral gold. Br J Rheumatol 1998;37:874-82.
76. YOCUM D, ALLARD S, COHEN SB et al.: Microemulsion formulation of cyclosporin (Sandimmun Neoral) vs Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. Rheum 2000;39:156-64.
77. WEINBLATT ME, KREMER JM, COBLYN JS et al.: Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.
78. SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. Lancet 1999;353:259-66.
79. STRAND V, TUGWELL P, BOMBARDIER C et al.: Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1870-8.
80. TRENTHAM DE, DYNESIUS-TRENTHAM RA, ORAV EJ et al.: Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993;261:1727-30.
81. FURST D, FELSON D, THOREN G, GENDREAU RM: Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomized trial. Therapeutic Apheresis 2000;4:363-73.
82. WOODWORTH TG: Early clinical studies of IL-2 fusion toxin in patients with severe rheumatoid arthritis and recent onset insulin-dependent diabetes mellitus. Clin Exp Rheumatol 1993;11(Suppl. 8): S177-S180.
83. SNOWDEN JA, BIGGS JC, MILLIKEN ST et al.: A randomized, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis. Bone Marrow Transplant 1998;22:1035-41.
84. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
85. BRESNIHAN B. ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
86. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
87. SOKKA T, PINCUS T: Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003;30:1138-46.
88. SOKKA T, PINCUS T: Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003;48:313-8.
89. GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: twoyear radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
90. LIPSKY PE, VAN DER HEIJDE D M F M, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
91. YAZICI Y, ERKAN D: Eligibility of rheumatoid arthritis patients seen in clinical practice for rheumatoid arthritis clinical trials: comment on the article by Sokka and Pincus. Arthritis Rheum 2003;48:3611.
92. GOGUS F, YAZICI Y, YAZICI H: Inclusion criteria as widely used for rheumatoid arthritis clinical trials: patient eligibility in a Turkish cohort. Clin Exp Rheumatol 2005;23:681-4.
93. WOLFE F, MICHAUD K: The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol 1994;21:1227-37.
94. SOKKA T, PINCUS T: Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 2009;36:1387-90.
95. HOCHBERG MC, TRACY JK, FLORES RH: "Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate. Ann Rheum Dis 2001;60: III51-III54.
96. BOERS M: Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard? Arthritis Rheum 2003;48:1481-3.
97. BRAUN J, SIEPER J, VAN DER HD: Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis: a preliminary proposal. Ann Rheum Dis 2003;62:1023-4.
98. PINCUS T, SWEARINGEN CJ, LUTA G, SOKKA T: Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis 2009;68:1715-20.
99. KLARESKOG L, VAN DER HEIJDE D, DE JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
100. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
101. KREMER JM, GENANT HK, MORELAND LW et al.: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76.
102. EMERY P, FLEISCHMANN R, FILIPOWICZ-SOSNOWSKA A etal: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, doubleblind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
103. KEYSTONE E, VAN DER HEIJDE D, MASON D, JR. et al.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, doubleblind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
104. KAY J, MATTESON EL, DASGUPTA B et al.: Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75.
105. MAINI RN, TAYLOR PC, SZECHINSKI J et al.: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
106. MAINMAN H, MCCLAREN E, HEYCOCK C, SARAVANAN V, HAMILTON J, KELLY C: When should we use parenteral methotrexate? Clin Rheumatol 2010.
107. VAN DER HEUDE D, LANDEWÉ R, KLARESKOG L et al.: Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study. Arthritis Rheum 2005;52:49-60. (Pubitemid 40129232)
108. YAZICI Y, YAZICI H: Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis. Clin Exp Rheumatol 2008;26:449-52.
109. YAZICI Y, SOKKA T, PINCUS T: Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am 2009;35:723-9.
110. PINCUS T, FERRACCIOLI G, SOKKA T et al.: Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology 2002;41:1346-56.
111. LANDEWÉ R, VAN DER HEUDE D: Radiographic progression depicted by probability plots: presenting data with optimal use of individual values. Arthritis Rheum 2004;50:699-706.
112. SOKKA T, ABELSON B, PINCUS T: Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008;26(Suppl. 51): S35-S61.
113. ST. CLAIR EW, VAN DER HEIJDE DM, SMOLEN JS et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
114. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.